Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.
We are a thriving, collaborative, creative community of 110 people with diverse talents, beliefs, and experiences headquartered in Cambridge, Massachusetts.
Delve further. Please visit www.generationbio.com or follow @generationbio. To see additional roles, please also check out https://generationbio.com/careers/
SUMMARY
Generation Bio seeks a highly motivated Scientist to support analytical activities in a cross-platform function. The successful candidate will work part of an analytics team responsible for developing, optimizing, and qualifying analytical assays, as well as performing experiments to better characterize and understand the Biophysical and Biochemical properties of Drug Substance and Lipid Nanoparticle Drug Product.
RESPONSIBILITIES:
- The successful candidate will focus on chromatography and mass spectrometry methods, develop and execute new assays to characterize ctLNP and impurities in Drug substance. Communicate results to cross-functional groups.
- Develop, qualify, and/or validate LC/MS methods for the quantitation of various types of biomolecules, particularly lipids, proteins, nucleic acids, and Oligos.
- Perform research drug substance and drug product characterization testing.
- Write/review method-specific development reports and SOPs; Monitor, trend and analyze Biophysical and Biochemical assays performance.
- Perform laboratory equipment preventative maintenance as needed.
- Provide mass spectrometry support to scientists in other groups.
QUALIFICATIONS:
- Ph.D. in Analytical chemistry, biochemistry or related sciences with experience in academic or pharmaceutical/biotech. B.S./M.S. with a minimum of 6 years of experience will be considered.
- Must have experience in mass spectrometry techniques including analysis of intact biomolecules, MS-based fragmentation techniques, and peptide quantification.
- Strong experience analyzing large molecules, peptides, or oligonucleotides using liquid chromatography including IP-RPLC, HILIC, IEX, etc.
- Strong chemical understanding of nucleic acids, peptides and other biomolecules.
- Strong communication and interpersonal skills to successfully collaborate with other groups.
POSITION: FTE, Exempt
EEOC Statement: Generation Bio believes in a diverse environment and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race (to include traits historically associated with race including, but not limited to, hair texture, hair type, hair length, and protective hairstyles such as braids, locks, twists, hair coverings, and Bantu knots), color, gender, religion, national origin, gender identity, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Generation Bio will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Top Skills
What We Do
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
 PNG file.png)
